| 注册
首页|期刊导航|中国中医眼科杂志|芪参益气明目方治疗m.3460G>A型Leber遗传性视神经病变的疗效分析

芪参益气明目方治疗m.3460G>A型Leber遗传性视神经病变的疗效分析

朱佳美 周剑 闫晓玲 苏艳 罗现科 杨昌璐 于欣宁 李朝妍 龚文心

中国中医眼科杂志2026,Vol.36Issue(5):415-420,470,7.
中国中医眼科杂志2026,Vol.36Issue(5):415-420,470,7.DOI:10.13444/j.cnki.zgzyykzz.2026.05.003

芪参益气明目方治疗m.3460G>A型Leber遗传性视神经病变的疗效分析

Efficacy Analysis of Qishen Yiqi Mingmu Formula in Treating m.3460G>A Leber He-reditary Optic Neuropathy

朱佳美 1周剑 2闫晓玲 2苏艳 2罗现科 1杨昌璐 1于欣宁 1李朝妍 1龚文心1

作者信息

  • 1. 北京中医药大学,北京 100029
  • 2. 北京中医药大学东方医院,北京 100078
  • 折叠

摘要

Abstract

OBJECTIVE To evaluate the clinical efficacy of Qishen Yiqi Mingmu Formula in treating m.3460G>A Leber hereditary optic neuropathy(LHON)with Qi deficiency and blood stasis syndrome.METHODS Medical records of 16 patients(32 eyes)diagnosed with m.3460 G>A LHON and Qi deficiency and blood stasis syndrome via mitochondrial DNA testing,who attended the Ophthalmology Department of Dongfang Hospital,Beijing University of Chinese Medicine between December 2016 and December 2024,were included.For observing best corrected visual acuity(BCVA),cases with disease duration≤12 months were assigned to Group A(nine cases,18 eyes),and those with duration>12 months to Group B(seven cases,14 eyes).For visual field[mean defect(MD),mean sensitivity(MS)]index analysis,patients were divided into Group Gtop and Group LVC(eight cases each,16 eyes each)based on the testing program used.A clinical database was established,and BCVA,visual field indices,and retinal nerve fiber layer(RNFL)thickness before and after treatment were compared and analyzed for correlations.RESULTS(1)BCVA:Post-treatment BCVA significantly decreased compared to pre-treatment in all 16 patients(t=3.111,P=0.002).Both Group A and Group B showed significant improvement in BCVA after treatment(tA=2.324,P=0.020;tB=2.251,P=0.024).Pre-treatment BCVA was significantly lower in Group A than in Group B(t=2.749,P=0.005);However,comparison of BCVA and BCVA changes between the two groups after treatment showed no statistically significant difference.(P>0.05).(2)MD:Post-treatment MD was significantly lower than pre-treatment in all 16 patients(t=4.651,P=0.000).Both Group Gtop and Group LVC showed significantly lower MD after treatment(tGtop=3.036,P=0.008;tLVC=3.559,P=0.003).Compared between the two groups,MD in the Gtop group was lower than that in the LVC group both before and after treatment,and the differences were statistically significant(tbefore treatment=2.326,P=0.027;tafter treatment=2.586,P=0.015).(3)MS:Post-treatment MS was significantly higher than pre-treatment in all 16 patients(t=4.218,P=0.000).Both Group Gtop and Group LVC showed significantly higher MS after treatment(tGtop=2.528,P=0.023;tLVC=3.546,P=0.003).There was no statistically significant difference in MS and MS changes between the two groups before and after treatment(all P>0.05).(4)RNFL thickness:No statistically significant differences were found in the average peri-papillary RNFL thickness or the thickness in the inferior,superior,nasal,and temporal quadrants before and after treatment(all P>0.05).(5)BCVA correlation analysis:BCVA (LogMAR) was positively correlated with age and negatively correlated with disease duration,both with statistical significance(rage=0.383,P=0.030;rduration=-0.450,P=0.010).BCVA showed no significant correlation with MD,MS,or average RNFL thickness(P>0.05).(6)BCVA multivariate regression analysis:Disease duration had a statistically significant impact on BCVA(t=4.402,P=0.000),while age,MD,and MS did not show significant effects(P>0.05).CONCLUSIONS Qishen Yiqi Mingmu Formula can,to some extent,improve BCVA and MS values,reduce MD values,and effectively enhance visual function in patients with m.3460G>A LHON.

关键词

Leber遗传性视神经病变/m.3460G>A位点/芪参益气明目方/视功能

Key words

Leber's hereditary optic neuropathy/m.3460G>A locus/Qishen Yiqi Mingmu Formula/visual function

分类

医药卫生

引用本文复制引用

朱佳美,周剑,闫晓玲,苏艳,罗现科,杨昌璐,于欣宁,李朝妍,龚文心..芪参益气明目方治疗m.3460G>A型Leber遗传性视神经病变的疗效分析[J].中国中医眼科杂志,2026,36(5):415-420,470,7.

基金项目

1 国家自然科学基金项目(82274587)2 北京中医药大学东方医院中央高水平中医医院项目(2025XZYJ17、DFRCZY-2024GJRC008、2024-DYZJ-00) (82274587)

中国中医眼科杂志

1002-4379

访问量0
|
下载量0
段落导航相关论文